Sorafenib

규격

284461-73-0CAS 번호

608-209-4EC 번호

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamideIUPAC 명칭

C21H16ClF3N4O3화학식

464.8 g/mol분자량

Sorafenib; 284461-73-0; BAY 43-9006; sorafenibum; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; DTXSID7041128; BAY-43-9006; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; 9ZOQ3TZI87; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; BAY-439006; CHEBI:50924; BAY 439006; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N(SUP 2)-METHYLPYRIDINE-2-CARBOXAMIDE; 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-N-methylpyridine-2-carboxamide; 4-(4-((4-chloro-3-(trifluoromethyl)phenyl)carbamoylamino)phenoxy)-N-methylpyridine-2-carboxamide; RefChem:6252; BAY-545-9085; sorafenib tosilate hydrate; DTXCID5021128; L01XE05; BAY 673472; BAY5459085; BAY 43 9006; BAY 5459085; BAY 545 9085; BA4 43 9006; 608-209-4; 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE; MFCD06411450; Sorafenib free base; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; C21H16ClF3N4O3; CHEMBL1336; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib [INN]; Sorafenib (Nexavar); MLS002415564; BAX; NSC-724772; NCGC00167488-01; SMR001339079; 284461-73-0 (free base); UNII-9ZOQ3TZI87; Sorafenib [USAN:INN:BAN]; SR-00000000529; HSDB 8173; 1uwh; 3gcs; 3heg; 4asd; Hit compound, 8; Sorafenib (Base); Sorafenib, 4; 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; BAY 43-9006; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; Nevaxar; Sorafenib; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid; Manganese(4+), chloro[[4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis[1-methylpyridiniumato]](2-)]-, chloride (1:4), (SP-5-12)-; Sorafenib (Standard); BAY43-9006; Kinome_766; SORAFENIB BASE; SORAFENIB [MI]; Sorafenib (USAN/INN); SORAFENIB [USAN]; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide;4-methylbenzenesulfonic acid; Nexavar (TN) (Bayer); SORAFENIB [VANDF]; SORAFENIB [MART.]; EC 608-209-4; SCHEMBL8218; SORAFENIB [WHO-DD]; SORAFENIB [EMA EPAR]; Sorafenib - Bio-X trade mark; BAY 43-9006; Sorafenib; cid_216239; cid_406563; GTPL5711; orb1225434; orb1310944; SCHEMBL29349634; BDBM16673; BDBM79601; GLXC-90094; HMS2043A18; HMS3244A15; HMS3244A16; HMS3244B15; HMS3656N20; HMS5085J14; K00597a; EX-A2894; BAY439006; EBC-00643; HY-10201R; NSC747971; NSC800934; s7397; T0093L; Sorafenib for peak identification CRS; AKOS005560229; AC-1674; CCG-269400; CS-1590; DB00398; FS10807; NSC-747971; NSC-800934; PB14443; SB19942; SDCCGSBI-0634413.P005; SF-0529; BAY-43-0006; NCGC00167488-02; NCGC00167488-03; NCGC00167488-04; NCGC00167488-05; NCGC00167488-07; NCGC00167488-11; NCGC00167488-14; NCGC00167488-21; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; BP-44051; BS164413; DA-52659; HY-10201; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; Sorafenib free base (BAY-43-9006)?; SY009239; PA-216239; NS00005946; SW202562-4; D08524; EN300-120647; AB00933189-05; AB00933189-06; AB00933189_08; B030968; Q421136; SR-00000000529-1; BRD-K23984367-001-01-8; BRD-K23984367-001-07-5; BRD-K23984367-075-15-2; Z89277543; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido) phenoxy)-N-methylpicolinamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)phenoxy)-N-methylpicolinamide; N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)- N-methylpyridine-2-carboxamide; 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide; 4-[4-[[[4-chloro-3-(trifluoromethyl)anilino]-oxomethyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide;4-methylbenzenesulfonic acid; 4-[4-[[4-chloranyl-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide;4-methylbenzenesulfonic acid; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-pyridine-2-carboxamide; Manganese(4+), chloro[[4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl-N21,N22,N23,N24)tetrakis[1-methylpyridiniumato]](2-)]-, chloride (1:4), (SP-5-12)-; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea동의어